Transforming Neurodegenerative Care

We are dedicated to developing stable, pharmaceutical-grade Psilocin treatments designed to address the unique challenges of neurodegenerative diseases. By focusing on creating condition-specific formulations, we aim to unlock the therapeutic potential of Psilocin, delivering science-driven, targeted care that meets the distinct needs of each condition.

Our mission is to pioneer innovative treatments, offering hope and improved quality of life for patients through precision medicine and cutting-edge research.

Leveraging our Innovative Psilocin Formulation Strategy will enable us to deliver controlled microdoses specifically for Neurodegenerative diseases. Through preclinical and clinical testing, we aim to assess the safety and efficacy of psilocin for a specific condition, paving the way for future regulatory approval as a pharmaceutical treatment.

Applying pharmaceutical standards and a traditional drug development strategy we will produce safe, effective, and disease-modifying therapies and controlled microdoses for Neurodegenerative diseases like Amyotrophic Lateral Sclerosis (ALS), Parkinson’s (PD), and Alzheimer’s (AD).

As presented at the ALS TDI Summit 2023. 

Scroll to Top